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Diabetic cardiomyopathy and nephropathy are two major causes of death of patients with diabetes. Extra generation of reactive
oxygen species (ROS), induced by hyperglycemia, is considered as the main reason for the development of these diabetic
complications. Transcription factor, NFE2-related factor 2 (Nrf2), is a master regulator of cellular detoxiﬁcation response and
redox status, and also provides a protective action from various oxidative stresses and damages. Recently we have demonstrated its
important role in determining the susceptibility of cells or tissues to diabetes-induced oxidative stress and/or damage. Therefore,
this review will speciﬁcally summarize the information available regarding the eﬀect of Nrf2 on the diabetic complications with
a focus on diabetic cardiomyopathy and nephropathy. Given the feature that Nrf2 is easily induced by several compounds, we
also discussed the role of diﬀerent Nrf2 activators in the prevention or therapy of various diabetic complications. These ﬁndings
suggest that Nrf2 has a potential application in the clinic setting for diabetic patients in the short future.
1.Introduction
Generally speaking, diabetic cardiovascular complications
include macrovascular disease (e.g., stroke and atheroscle-
rosis) and microvascular disease (e.g., retinopathy and
nephropathy) [1]. Diabetic nephropathy as one of microvas-
cular diseases and diabetic cardiomyopathy as one of
macrovascular diseases are two common complications of
diabetes and also two main causes of the mortality for
diabetic patients. The prevention of diabetic nephropathy
and cardiomyopathy has become a global concern for those
whoareworkingindiabeticcareandmanagement.Although
glucose control, blood pressure, lipid lowering, and the
blockade of the renin-angiotensin system [2] were used
for the treatment of diabetic patients, the development
and progression of nephropathy and cardiomyopathy in the
patients with diabetes remains unpreventable. Therefore,
to develop an eﬀective approach to prevent or delay the
development and progression of these lethal complications
for diabetic patients is urgently needed.
Hyperglycemia, hyperlipidemia and inﬂammation were
three main metabolic abnormalities in diabetes, all which are
able to stimulate generation of reactive oxygen or nitrogen
species (ROS or RNS). Extra generation of these species
is known to be critically causative of the development of
diabetic complications, including diabetic nephropathy and
cardiomyopathy [3–6]. Therefore, antioxidant prevention or
therapy of diabetic complications has been attractive, but
to date, there was no any antioxidant that was found to be
eﬃciently applied in clinics [4–6].
The transcription factor NFE2-related factor 2 (Nrf2) as
onememberofthecap’n’collarfamilyisamasterregulatorof
cellular detoxiﬁcation responses and redox status [9, 10]. As
illustrated in Figure 1, under physiological conditions Nrf2
locates in the cytoplasm and combines with its inhibitor
kelch-like ECH-associated protein 1 (KEAP1) [11]. KEAP1
could mediate a rapid ubiquitination and subsequent degra-
dation of Nrf2 by the proteasome [11]. Upon exposure of
cells to oxidative stress or electrophilic compounds, Nrf2
is free from KEAP1 and translocates into the nucleus to2 Experimental Diabetes Research
bind to antioxidant-responsive elements (AREs) in the genes
encoding antioxidant enzymes such as NADPH quinone
oxidoreductase (NQO1), glutathione S-transferase, heme
oxygenase-1 (HO1), and γ-glutamylcysteine synthetase,
increasing their expression to play a role of detoxiﬁcation,
antioxidation, and anti-inﬂammation [11, 12].
Recently, several studies have indicated preventive eﬀect
of Nrf2 on high glucose- (HG-) induced oxidative damage in
the cultured cells and potentially on the diabetic complica-
tions in animal models [13]. Although a few good reviews
on the general features of Nrf2 in the oxidative stress and
damage related to diabetes are available now [14, 15], we
would like to brieﬂy review the information in terms of
the protective role of Nrf2 in the development of diabetic
complications with a speciﬁc focus on nephropathy and
cardiomyopathy.GiventhefeaturethatNrf2iseasilyinduced
by several compounds, we also discussed the eﬀect of several
Nrf2 activators in the prevention or therapy of these two
major complications.
2.DiabetesUpregulates Nrf2 Expressionand
Functioninthe Heart andKidney
It is known that Nrf2 expression and function in the cells
in vitro and tissues in vivo are increased in response to
oxidative stress. Since several studies have indicated that
the induction of ROS and/or RNS by HG in the cultured
cardiovascularcellsandrenalcells,whetherHGcouldelevate
the Nrf2 expression and activation and its downstream gene
expression in these cells has been investigated [13, 16, 17].
Treatment with glucose at 20 and 40mM for 24h increased
the expression of Nrf2 mRNA in primary cardiomyocytes
or H9C2 cardiac cell line. NQO1, a prototype of Nrf2-
regulated chemical-detoxiﬁcation gene, was induced to be
overexpressed in cardiomyocytes by such HG exposure
too. Immunoblotting conﬁrmed the protein expression and
induction of Nrf2 and HO1 in cardiomyocytes. Immunoﬂu-
orescent confocal microscopic examination of the cells
revealed that HG treatment signiﬁcantly increased the
nuclear and total cell staining of Nrf2 in comparison with
the control cells, indicating that glucose indeed increased
the protein level and nuclear accumulation of Nrf2 [16].
Used human mesangial cells (HRMCs), Jiang et al. also
demonstrated HG-induced elevation of nuclear protein level
ofNrf2alongwithupregulationofthemRNAlevelofNQO1,
HO-1, and GST [17]. To further conﬁrm the notion that
Nrf2 activation by HG is through generation of ROS, N-
acetylcysteine (NAC), an ROS scavenger, was included in the
medium. As expected, NAC inhibited the activation of HG-
induced Nrf2 and NQO1. In addition, HG-induced Nrf2
activation in other cells such as endothelial cells [13, 18]
and vascular smooth muscle cells [19] was also reported.
Collectively, these results indicate that HG or hyperglycemia
is able to activate the Nrf2 pathway through generation of
ROS.
Upregulation of Nrf2 and/or its downstream antioxidant
genes in response to hyperglycemia were found not only
in the cultured cells, but also in the heart and kidney
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Figure 1: The simpliﬁed regulation of Nrf2 by Keap1 and the
mechanism of MG132 to activate Nrf2. In general condition,
Nrf2 combined with Keap1 in cytoplasm. Under oxidative stress,
Nrf2 is free from Keap1 and translocates into nuclear. Through
binding with antioxidant response element (ARE), Nrf2 regulates
the expression of its downstream target genes to prevent oxidative
stress and damage. MG132 could prevent Nrf2 degradation by
inhibiting proteasome (adapted from [7, 8]).
of diabetic mice that were also observed. We have used
C57BL/6 mice to make type 1 diabetes with a single dose of
streptozotocin (STZ). At two weeks after hyperglycemia, we
found a signiﬁcant upregulation of Nrf2 downstream genes
NQO1 and HO1 mRNA expression [16]. Jiang et al. have
examined if Nrf2 is activated in the kidney of STZ-induced
diabeticmice.TheyusedmultiplelowdosesofSTZtoinduce
type 1 diabetes in C57BL/6 mice. At 16 weeks postinjection,
Nrf2 expression in the glomeruli of diabetic mice was greatly
enhancedandNrf2nuclearstainingwasobserved.Activation
of Nrf2 was conﬁrmed by upregulation of NQO1 in the
glomeruli of diabetic mice [17].
Diabetes-upregulated activation of Nrf2 expression was
also observed in the kidney and heart of diabetic patients.
In the study by Jiang et al., the diabetic nephropathy
kidney tissues were obtained from patients with proteinuria
that underwent a renal biopsy for diagnosis of diabetic
nephropathy and nondiabetic patients as control. They
used these normal and diabetic nephropathy glomeruli to
perform immunohistochemical analysis, showing that Nrf2
was hardly expressed in normal glomeruli, whereas it was
upregulated in diabetic nephropathy glomeruli. In addition,
cells with high expression of Nrf2 in the nucleus were
identiﬁed as mesangial cells. NQO1 was also activated inExperimental Diabetes Research 3
glomeruli of the patients with diabetic nephropathy [17]. In
contrast with diabetic nephropathy patients, Tan et al. have
demonstrated a diﬀerent ﬁnding in terms of Nrf2 expression
in the cardiac tissue from diabetic patients and control [20].
Tissue sections of left ventricles were obtained from autopsy
heart specimens of humans with or without diabetes (all
diabetic males had histories of hypertension and cardiac
dysfunction). Nrf2 expression in the nuclei was signiﬁcantly
downregulated compared to control heart. Reasons for
the discrepancy between diabetic kidney and heart remain
unclear now based on the limited date. However, several
possibilities should be kept in mind: (1) case numbers are
too small; (2) organ’s diﬀerent responses may be related; (3)
tissues from control groups may be an important issue since
what these patients were exposed to were unclear; (4) the last
is the period of diabetes history.
In support of the last notion listed above, our recent
ﬁnding demonstrated that Nrf2 protein expression was
slightly increased in the heart of mice with two months
hyperglycemia but signiﬁcantly decreased in the heart of
micewith5monthshyperglycemia[20].Combinedourearly
study [16] in which Nrf2 downstream genes were increased
in the heart of diabetic mice at 2 weeks after STZ-induced
hyperglycemia, we assume that Nrf2 is adaptively trying to
remain functional to overcome diabetic damage at the early
stage of diabetes. At the late stage of diabetes, however,
cardiac antioxidant function is further impaired, leading
to a decrease in cardiac Nrf2 expression. Therefore, these
above studies imply the preventive function of Nrf2 against
diabetes-induced oxidative damage.
3. Downregulation of Nrf2 Gene
Accelerates DiabeticPathological Effect on
theHeartandKidney
To gain insight into the role of Nrf2 in prevention of diabetic
complication, Yoh et al. have performed the ﬁrst study using
Nrf2-KO mice [21]. They used STZ to induce diabetes in
both Nrf2-KO and their wild-type (WT) C57BL/6 mice and
found that compared to WT diabetic mice, Nrf2-KO diabetic
mice exhibited a deterioration of renal function gradually
over the 10-week observation period, along with urinary
excretion of nitric oxide metabolites and the occurrence
of 8-nitroguanosine, as index of glomerular lesions, during
the early stages after treatment. The increased susceptibility
of Nrf2-KO mice to diabetes-induced renal damage was
further and systemically examined by Jiang et al. [17]. In
this study, they used STZ to induce diabetes with Nrf2-KO
and WT mice and demonstrated the following evidence:
(1) at 16 weeks post-injection, Nrf2-KO diabetic mice
showed higher renal ROS production, greater oxidative DNA
damage and renal injury compared with WT diabetic mice;
(2) Nrf2-KO diabetic mice had more severe glomerular
injury than WT diabetic mice, shown by increased glycogen
deposition and severe glomerulosclerosis; (3) Nrf2-KO mice
had higher TGF-β1 transcription and ﬁbronectin expression,
this work clearly indicates a protective role of Nrf2 in
diabetic nephropathy; (4) to directly link the Nrf2 to the
renal protection from diabetes, particularly hyperglycemia,
they used human renal mesangial cells to show that HG-
induced signiﬁcant increase in the expression of several
ﬁbrotic mediators, including TGF-β1 ,c o u l db ee n h a n c e db y
knockdown of Nrf2 by siRNA.
In consistence with the renal protection of Nrf2 from
diabetes, we demonstrated that HG-induced ROS generation
in both primary neonatal and adult cardiomyocytes from
the WT mouse heart, whereas, in the cardiomyocytes
from Nrf2-KO mice, ROS was signiﬁcantly higher under
basal conditions and HG remarkably further increased ROS
production in concentration and time-dependent manners
[16]. In addition, HG also induced signiﬁcantly higher levels
of apoptosis at lower concentrations and in shorter time
in Nrf2-KO cardiomyocytes than in WT cardiomyocytes.
Primary adult cardiomyocytes from control and diabetic
mice that was induced by STZ also showed dependence on
Nrf2 function for isoproterenol-stimulated contraction [16].
In fact, Nrf2 activation not only protects the kidney and
heart from diabetes-induced oxidative damage, but also the
other organs from diabetes. For instance, Ungvari et al. have
tried to elucidate the homeostatic role of adaptive induction
of Nrf2-driven free-radical detoxiﬁcation mechanisms in
endothelial protection under diabetic conditions. They fed
bothNrf2-KOandWTmicewithhigh-fatdiet(HFD).HFD-
induced increases in vascular ROS levels and endothelial
dysfunction were signiﬁcantly greater or more severe in
Nrf2-KO mice than WT mice [18].
4. Prevention of Diabetic Complications by
Activation of Nrf2 with Various Activators
The information from the above parts indicates that Nrf2 as
an adaptive mechanism is upregulated in the cells exposed to
HG or tissues of diabetic animals and patients. Deletion of
Nrf2 gene causes a signiﬁcant increase in the susceptibility of
cells or tissues to HG- or diabetes-induced oxidative dam-
age and dysfunction, as illustrated in Figure 2. Therefore,
upregulation of Nrf2 expression and function by various
approaches may provide a preventive eﬀect on diabetes-
induced oxidative damage and consequent complications, to
support of which several studies have been done with very
multiple beneﬁcial eﬀects on the diabetic complications, as
summarized in Table 1.
4.1. In Vitro Evidence. The ﬁrst study using Nrf2 activator
to prevent HG-induced damage was done by Xue et al.
[13]. They used sulforaphane (SNF) to induce nuclear
translocation of Nrf2 with signiﬁcant increases in its down-
stream antioxidant genes such as three- to ﬁve-fold increased
expression of transketolase and glutathione reductase [13].
SNF treatment signiﬁcantly prevented HG: increased the
formation of ROS and the activation of the hexosamine
and PKC pathways, both which have been well deﬁned
as important cellular changes in diabetic eﬀect on the
target organs. After this study, several other studies with
diﬀerent Nrf2 activators in diﬀerent kinds of cells also
reported similar preventive eﬀects on HG-induced oxidative4 Experimental Diabetes Research
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Figure 2: The protection by Nrf2 activation from diabetic
nephropathy. Two main pathogenic factors leading to diabetic
nephropathy in diabetic patients are increased ROS/RNS and extra-
cellular matrix (ECM) accumulation. Activation of Nrf2 by SNF,
CA, tBHQ, and Keap1 SiRNA or activation of Nrf2’s downstream
targets genes such as NQO1 and r-GCS plays an important role
in preventing ROS/RNS-induced damage. At the same time, the
expression of TGF-β and P21 was inhibited, leading to a prevention
of ECM accumulation. Inhibition of Nrf2 in Nrf2-KO animals
or by Nfr2 siRNA resulted in an enhancing diabetic eﬀects. This
illustration was made mainly based on a published study [22].
damage (see Table 1). For instance, the eﬀects of magnesium
lithospermate B (LAB) against HG-induced oxidative stress
and damage via activation of Nrf2 have been evaluated in
vascular smooth muscle cells [19].
Zheng et al. have systemically examined the preventive
eﬀect of Nrf2 activation with its activators on HG-mediated
mesangial cell growth inhibition and hypertrophy. They
used human mesangial cell line (HRMC) and three kinds
of Nrf2 activators, tert-Butylhydroquinone (tBHQ), SNF,
or cinnamic aldehyde (CA). The growth curve for HRMCs
growing in HG media was found to be below compared
to those either growing in control or in HG with Nrf2
activators. Staining with Ki67 showed that hyperglycemia
inhibited cell proliferation, which was counteracted by
activation of Nrf2. The size of HRMCs growing in HG
was larger than those in control media, and the increased
HRMCs’ size induced by HG was signiﬁcantly improved by
three Nrf2 activators. Collectively, these results demonstrate
that hyperglycemia-induced cell growth inhibition, and that
hypertrophy can be attenuated by activation of the Nrf2
pathway. To gain molecular understanding of how Nrf2 acti-
vation relieves HRMC hypertrophy and growth inhibition
under HG conditions, the expressions of TGF-β1 and its
downstreameﬀectorswerefurtheranalyzed.Theyfoundthat
HG-induced upregulation of TGF-β1, ﬁbronectin, collagen
IV, and p21 in HRMCs was suppressed by treatment with
three Nrf2 activators.
4.2.InVivoEvidence. ThepreventiveeﬀectofNrf2activation
on diabetic complications in animal models has been
explored recently by several groups with diﬀerent activators
(see Table 1). Resveratrol, a red wine antioxidant and a
natural phytoalexin, has already been used in prevention and
therapyofcancer[33],regulationofbloodplateletfunctions,
and protection of cardiovascular diseases [34]. By treating
STZ-induce diabetic rats with resveratrol, Palsamy and Sub-
ramanian not only conﬁrmed the protection of resveratrol to
diabetic nephropathy but also found that resveratrol could
normalize the protein expression of Nrf2, and its down-
s t r e a mg e n e ss u c ha sγ-GCS and HO-1 in diabetic kidney
[31].Similarly bytreatingwith 1% tBHQin STZ-induce dia-
betic mice diet, Li et al. also demonstrated that renal expres-
sion of Nrf2 and downstream antioxidants increased along
with signiﬁcant decreases in the extracellular matrix depo-
sition and malondialdehyde concentrations in the glomeruli
compared to the diabetic mice with regular diet [28].
As mentioned in Section 1, under physiological condi-
tions, Nrf2 locates in the cytoplasm and combines with
its inhibitor Keap1 that leads to Nrf2 degradation by the
proteasome (Figure 1). It is known that MG132 acts as a
proteasome inhibitor, so that it may activate Nrf2 through
decreasing the degradation of Nrf2. Luo et al. have ﬁrst
explored the possible prevention of diabetic nephropathy
by activation of Nrf2 with MG132 [8]. They treated STZ-
induced diabetic rats with MG132 (10μg/kg) for 12 weeks
and they found the following important outcomes. (1)
Diabetes-increased 24-h urinary protein excretion rate and
renal pathological changes were all improved after MG132
administration.(2)Diabetes-enhancedrenal26Sproteasome
activity and concentration were eﬀectively reduced after
MG132 administration. (3) Diabetes-increased nitrosative
damages in kidneys were decreased after MG132 treatment.
(4) Renal mRNA and protein expressions of Nrf2 in diabetic
ratswereupregulatedbyMG132comparedtodiabetesalone.
Accordingly, diabetes-decreased renal mRNA expression of
superoxide dismutase 1 (SOD1), catalase, and glutathione
peroxidase (GPx) was restored after MG132 intervention.
(5) Diabetes-increased renal nuclear factor κB( N F - κB)
activity was inhibited after MG132 administration. These
data suggest that inhibition of the proteasome by MG132
has a preventive eﬀect on the development and progression
of diabetic nephropathy in rats through the upregulation of
Nrf2-dependent antioxidant genes (Figure 1).
In line with the above ﬁndings for the renal protec-
tion by MG132 activation of Nrf2, a series of synthetic
triterpenoids, CDDO, and CDDO-imidazolide as potent
inducers of Nrf2/ARE signaling has been developed and
used to prevent several diseases related to inﬂammatory
and oxidative damage [35–38]. Recently, a novel synthetic
triterpenoidderivative,dihydro-CDDO-triﬂuoroethylamide
(dh404), has been developed to activate Nrf2 and sup-
presses oxidative stress. Dh404 interrupted the Keap1-Cul3-
Rbx1 E3 ligase complex-mediated Nrf2 ubiquitination and
subsequent degradation saturating the binding capacity
of Keap1 to Nrf2, thereby rendering more Nrf2 to be
translocated into the nuclei to activate Nrf2-driven gene
transcription [39]. We have shown that activation of cardiac
Nrf2 by Dh404 in STZ-induced diabetic mice signiﬁcantly
prevented diabetes-induced cardiac oxidative damage and
insulin resistance [20]. More importantly, Bardoxolone
methyl (aka CDDO-Me or RTA 402) has been clinicallyExperimental Diabetes Research 5
Table 1: Nrf2 activators were treated to diabetic animals and cells.
Nrf2 activators Mechanisms Target organs Species Ways and volume References
Insulin Nuclear translocation Brain endothelial cell Human 100nM, 30min [23]
HMEC-1 endothelial cell Human 4mol/L, 6–48h [13]
Pancreatic islet
RIN cells
Mice
Rat
40μg/ k g ,I Pd a i l y ,8d a y s
10μM,3h [24]
Sulforaphane Disrupt the Keap1-Nrf2 complex
nuclear translocation Kidney Mice 12.5mg/kg,
p.o. 16 weeks [22]
Mesangial cells Human 1.25mmol/L
Nerve
Neuro2a cell Rat 0.5 and 1mg/kg, 6 weeks
5.5mM [25]
Oltipraz Nuclear translocation Liver Mice 150mg/kg, IP tertian, 5
times [26]
Adipose/muscle Mice 0.75g/kg p.o., 28 weeks [27]
tBHQ Enhance expression and nuclear
accumulation
Kidney Mice 1% p.o., 4 and 12 week [28]
Renal mesangial cells Human 6.25mmol/L [22]
MG132 Decrease degradation Kidney Rat 10μg/ k gI P ,d a i l y ,1 2w e e k s [ 8]
PETN Induce HO-1 Blood vessel Rat 15mg/kg/day, p.o. 7 weeks [29]
LAB Activate NQO1 Vascular smooth muscle cells
Vessel tissue Rat 50μmol/L
50mg/kg IP. daily, 15 days [19]
AGE-BSA Nuclear translocation Aortic endothelial cells Bovine 100μgmL −1, 0–24 hours [30]
Resveratrol Increase expression Kidney Rat 5mg/kg, p.o., 30 days [31]
DH404 Disrupt the Keap1-Nrf2 complex HL-1 cells
Heart Mice 200nmol/L, 12 hour
10mg/kg, IP., tertian 2 weeks [20]
CA Increase the expression kidney
mesangial cells
Mice
Human
25/50mg/kg, p.o., 16 weeks
5mmol/L [22]
Telmisartan Suppression of NAD(P)H
oxidase Kidney Mice 5mg/kg, p.o., 4 weeks [32]
Notes. RIN cells: rat pancreatic β-cell line RINm5F; HMEC-1 cells: human microvascular endothelial cells; tBHQ: tert-butylhydroquinone; PETN:
pentaerithrityl tetranitrate; LAB: magnesium lithospermate B; AGE-BSA: AGE-modiﬁed bovine albumin; CA: cinnamic aldehyde; HL-1 cells: adult murine
atrial cardiomyocyte tumor lineage p.o.: diet; IP: intraperitoneal injection.
explored and extensively discussed for its preventive and
therapeutic eﬀects on diabetic nephropathy [40–45].
Although the studies discussed above and others listed
in Table 1 have phenomenally suggested the involvement
of Nrf2 activation in the preventing diabetic nephropathy,
it remains unclear whether upregulated Nrf2 by these
activators such as resveratrol, tBHQ, or MG132 is really or
not the mediator to prevent complications. This uncertain
conclusion was solved by a recent systemic study by Zheng
et al. The beauty of the Zhang et al. study is that they
used two activators of Nrf2: SNF and CA to treat STZ-
induce diabetic model in both Nrf2-KO and WT mice
[22]. They demonstrated that the activation of Nrf2 and
its downstream targets NQO1 and γ-GCS could improve
metabolic disorder and alleviate renal damage in STZ-
induced WT diabetic mice, but not in Nrf2-KO diabetic
mice. This study conclusively indicates the requirement of
Nrf2 for SNF- and CA-induced renal protection against
diabetes [22].
Besides the studies discussed above, several other studies
also demonstrated the preventive eﬀects of Nrf2 activation
on diabetic complications with diﬀerent Nrf2 activators,
which are summarized in Table 1. It should be noted
that not all Nrf2 activators have the same eﬀects on the
activation of Nrf2 and its downstream target genes. For
instance, AGE-modiﬁed bovine albumin (AGE-BSA) could
induce Nrf2 nuclear translocation and enhanced mRNA and
protein expression of HO-1 and NQO1, but not glutathione
peroxidase-1. Treated with AGE-BSA (100μg/mL for 24h),
bovine aortic endothelial cells exhibited an adaptive endoge-
nous defense against oxidative stress in diabetes [30]. Pen-
taerithrityl tetranitrate (PETN), although did not activate
Nrf2, signiﬁcantly activated the expression and function of
HO-1, which signiﬁcantly improved endothelial dysfunction
in diabetes by reducing oxidative stress [29].
To further address the importance of Nrf2 downstream
protective genes in preventing diabetic complications, there
was a very important human study. It is known that NQO1,
one important Nrf2 downstream protective components, is
an important detoxifying enzyme. To address whether the
functional variants of NQO1 can reﬂect the development of
diabetic complications, Ramprasath et al. have analyzed the
genotypes of 539 type 2 patients and 285 controls in South
Indian population. It is found that the functional variants
of NQO1 were associated with the development of coronary
artery disease in people with type 2 diabetes [46]. There was6 Experimental Diabetes Research
an study, in which nonobese and hypoinsulinemic C57BL/6-
Ins2(Akita) (C57BL/6-Akita) diabetic mice were treated with
telmisartan, an angiotensin II type 1 receptor blocker, for 4
weeks. Vehicle-treated C57BL/6-Akita mice exhibited higher
renalNAD(P)Hoxidase(NOX)andlowerrenalSODactivity
with increased levels of renal superoxide than the C57BL/6-
wild-type nondiabetic mice. Interestingly, telmisartan treat-
ment not only reduced NOX activity but also enhanced SOD
activityinC57BL/6-Akitamousekidneys,leadingtoareduc-
tion of renal superoxide levels. Furthermore, telmisartan-
treated C57BL/6-Akita mice increased the renal protein
expressionofSODandNrf2.Inparallelwiththereductionof
renal superoxide levels, a reduction of urinary albumin levels
and a normalization of elevated glomerular ﬁltration rate
were observed in telmisartan-treated C57BL/6-Akita mice.
Finally, treatment of C57BL/6-Akita mice with apocynin, an
NOX inhibitor, also increased the renal protein expression
of SOD and Nrf2. Collectively, our data suggest that NOX
negatively regulates renal SOD, possibly by downregulation
of Nrf2, and that telmisartan could upregulate renal SOD
by the suppression of NOX and subsequent upregulation of
Nrf2,leadingtotheameliorationofrenaloxidativestressand
diabetic renal changes [32].
5. Conclusions
The prevalence of diabetes dramatically increases in world-
wide and its complications signiﬁcantly aﬀect the life quality
ofdiabeticpatients.Diabeticnephropathyandcardiomyopa-
thy are the two major causes for the mortality of diabetic
patients. However, there was no an eﬀective approach to pre-
vent the development of these complications for the patients
with diabetes. Recently, studies have indicated that Nrf2 as
a pivotal mediator for the antioxidant defense system in
our body plays a critical role in preventing diabetes-induced
oxidative stress/damage, inﬂammation, and organ’s dysfunc-
tion. Although there remain many questions to be further
investigated, the potential beneﬁcial eﬀects of upregulation
of Nrf2 and/or its downstream protective components
has attracted the attention of basic scientists and clinical
physicians to consider its potential application in the clinic.
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